干扰素α-2b对乙型肝炎患者肝功能、补体水平及氧化应激水平的影响

Effects of interferon α-2b on liver function, and level of complement and oxidative stress in patients with hepatitis B

目的:观察干扰素α-2b治疗对乙型肝炎患者肝功能、肝纤维化、补体蛋白及氧化应激水平的影响。方法:随机将我院收治的乙型肝炎患者100例分为对照组与观察组,每组50例。入院后,对照组给予恩替卡韦治疗;观察组给予干扰素α-2b联合恩替卡韦治疗。比较两组治疗前后血清中胆红素(TBil)、天门冬氨酸氨基转移酶(AST)、丙氨酸转氨酶(ALT)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)、补体C3蛋白(C3)、补体C4蛋白(C4)、丙二醛(MDA)、超氧化物歧化酶(SOD)及一氧化氮(NO)水平。结果:治疗结束后,两组血清中TBil、AST、ALT、PCⅢ、CⅣ、MDA及NO水平与治疗前比较均显著降低;C3、C4及SOD水平均显著升高(P<0.05);治疗结束后,观察组TBil、AST、ALT、PCⅢ、CⅣ、MDA及NO水平明显低于对照组,C3、C4及SOD水平明显高于对照组(P<0.05)。结论:干扰素α-2b与恩替卡韦联合用药治疗乙型肝炎具有较好的疗效,可显著改善患者肝功能及免疫功能,延缓肝脏纤维化进程,减轻氧化应激损伤,值得临床推广。

Objective: To observe the effect of interferon α-2 b treatment on liver function, liver fibrosis, complement protein and oxidative stress in patients with hepatitis B. Methods: A total of 100 patients with hepatitis B in our hospital were randomly divided into control group and observation group, with 50 cases in each group. After admission, patients in the control group were treated with entecavir, while patients in the observation group were treated with interferon α-2 b combined with entecavir. The levels of serum bilirubin(TBil), aspartate aminotransferase(AST), alanine aminotransferase(ALT), type III procollagen(PCIII), type IV collagen(CIV), complement C3 protein(C3), complement C4 protein(C4), malondialdehyde(MDA), superoxide dismutase(SOD) and nitric oxide(NO) were compared between the two groups before and after treatment. Results: After treatment, the levels of TBil, AST, ALT, PCIII, CIV, MDA and NO in serum of patients with hepatitis B in both groups were significantly lower than those before treatment, and the levels of C3, C4 and SOD were significantly higher than those before treatment(P<0.05). After treatment, the levels of TBil, AST, ALT, PC III, C IV, MDA and NO in serum of patients in the observation group were significantly lower than those in the control group, while the levels of C3, C4 and SOD in serum of patients in the observation group were significantly higher than those in the control group(P<0.05). Conclusion: The combination of interferon α-2 b and entecavir has a good curative effect on hepatitis B. It can significantly improve the liver function and immune function of patients, delay the process of liver fibrosis and reduce oxidative stress injury. It is worthy of clinical promotion.